Pliant Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLRX research report →
Range $3 – $3
Price Chart
About the company
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
- CEO
- Bernard Coulie
- IPO
- 2020
- Employees
- 49
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on PLRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.89M
- P/E
- -0.41
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.29
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.31%
- ROIC
- -61.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,696,000+0.0%
- Op Income
- $-150,073,000
- Net Income
- $-149,344,000+29.0%
- EPS
- $-2.43+30.0%
- OCF Growth
- +17.5%
- FCF Growth
- +19.2%
- 52W High
- $1.67
- 52W Low
- $0.57
- 50D MA
- $0.92
- 200D MA
- $1.12
- Beta
- 1.36
- RSI (14)
- 15
- Avg Volume
- 408.93K
No earnings-call transcripts are available for PLRX yet.
- Free Float
- 88.9%
- Shares Outstanding
- 61.99M
- Float Shares
- 55.09M
of shares held by institutions
88 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tang Capital Management LLC | 6.14M | 0 |
| Adar1 Capital Management, LLC | 5.51M | 0 |
| Vanguard Group Inc | 2.82M | ▲ 42.30K |
| Acadian Asset Management LLC | 2.42M | 0 |
| Vanguard Capital Management LLC | 2.41M | ▼ 31.89K |
| Two Sigma Investments, LP | 2.25M | ▼ 8.80K |
| Renaissance Technologies LLC | 2.05M | ▲ 4.49K |
| Monaco Asset Management Sam | 2.01M | ▲ 68.69K |
| Lynx1 Capital Management LP | 1.80M | 0 |
| Woodline Partners LP | 1.63M | ▲ 333.52K |
| Prosight Management, LP | 1.60M | ▲ 234.23K |
| Bml Capital Management, LLC | 1.55M | 0 |
Held by 33 ETFs
Biggest fund positions in PLRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Raben David | other | 575,000 |
| Sep 30, 26 | Raben David | other | 0 |
| Jul 9, 26 | Iannone Robert | other | 0 |
| Jul 9, 26 | Iannone Robert | other | 60,000 |
| Jul 9, 26 | Borellini Flavia | other | 0 |
| Jul 9, 26 | Borellini Flavia | other | 60,000 |
| Jun 11, 26 | CROWELL GAYLE A | other | 70,000 |
| Jun 11, 26 | MCCOURT Thomas A | other | 70,000 |
| Jun 11, 26 | Krognes Steve E. | other | 70,000 |
| Jun 11, 26 | Curnutte John T | other | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLRX coverage
Recent articles, reports, and earnings notes.
No research on PLRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLRX report →Head-To-Head Comparison: Pliant Therapeutics (NASDAQ:PLRX) versus TG Therapeutics (NASDAQ:TGTX)
defenseworld.net · Nov 21
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com · Nov 9
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com · Oct 29
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
globenewswire.com · Oct 20
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
globenewswire.com · Oct 19
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
globenewswire.com · Sep 30
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
defenseworld.net · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.